vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet